Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives

One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

Yao, J. C., Hassan, M. M., Phan, A. T., Dagohoy, C. G., Leary, C. C., Mares, J. E., Abdalla, E. K., Fleming, J. B., Vauthey, J., Rashid, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4377 · Cited by 4,510 · see citing works

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

Dasari, A. N., Shen, C., Halperin, D. M., Zhao, B., Zhou, S., Xu, Y., Shih, Y. T., & Yao, J. C. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0589 · Cited by 3,457 · see citing works

Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors

Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308 · see citing works

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

Yao, J. C., Shah, M. H., Ito, T., Lombard‐Bohas, C., Wolin, E. M., Cutsem, E. V., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,879 · see citing works

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

Raymond, É., Dahan, L., Raoul, J., Bang, Y., Borbath, I., Lombard‐Bohas, C., Valle, J. W., Metrakos, P. P., Smith, D. M., Vinik, A. I., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003825 · Cited by 2,567 · see citing works

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

Rinke, A., Müller, H., Schade‐Brittinger, C., Klose, K., Barth, P. J., Wied, M., Mayer, C., Aminossadati, B., Pape, U., Bläker, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8510 · Cited by 2,507 · see citing works

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

Caplin, M. E., Pavel, M. E., Ćwikła, J. B., Phan, A. T., Raderer, M., Sedláčková, E., Cadiot, G., Wolin, E. M., Capdevila, J., Wall, L. R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316158 · Cited by 1,937 · see citing works

Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart

Travis, W. D., Brambilla, E. M., BURKE, A. P., Marx, A., & Nicholson, A. G. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000663 · Cited by 1,910 · see citing works

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

Yao, J. C., Fazio, N., Singh, S., Buzzoni, R., Carnaghi, C., Wolin, E. M., Tomášek, J., Raderer, M., Lahner, H., Voi, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00817-x · Cited by 1,290 · see citing works

Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Pavel, M. E., Öberg, K., Falconi, M., Krenning, E. P., Sundin, A., Perren, A. A., & Berruti, A. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.304 · Cited by 1,191 · see citing works

Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

Faivre, S. J., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., Bello, C. L., DePrimo, S. E., Brega, N. M., Massimini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2194 · Cited by 1,162 · see citing works

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

Pavel, M. E., Hainsworth, J. D., Baudin, É., Peeters, M., Hörsch, D., Winkler, R. E., Klimovsky, J., Lebwohl, D., Jehl, V., Wolin, E. M., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61742-x · Cited by 1,054 · see citing works

ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site

Pavel, M. E., O’Toole, D., Costa, F. P., Capdevila, J., Gross, D., Kianmanesh, R., Krenning, E. P., Knigge, U., Salazar, R., Pape, U., et al. (2016) · Neuroendocrinology · doi:10.1159/000443167 · Cited by 1,038 · see citing works

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study

Sørbye, H., Welin, S., Langer, S. W., Vestermark, L. W., Jessen, N. H., Osterlund, P. J., Dueland, S., Hofsli, E., Guren, M. G., Öhrling, K., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds276 · Cited by 1,031 · see citing works

SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile

Bruns, C., Lewis, I., Briner, U., Meno-Tetang, G., & Weckbecker, G. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460707 · Cited by 692 · see citing works

Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study

Yao, J. C., Phan, A. T., Chang, D. Z., Wolff, R. A., Hess, K. R., Gupta, S. K., Jacob, C., Mares, J. E., Landgraf, A., Rashid, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7858 · Cited by 649 · see citing works

Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial

Yao, J. C., Lombard‐Bohas, C., Baudin, É., Kvols, L. K., Rougier, P. R., Ruszniewski, P. B., Hoosen, S., Peter, J. S., Haas, T., Lebwohl, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2669 · Cited by 648 · see citing works

Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Shah, M. H., Goldner, W. S., Benson, A. B., Bergsland, E. K., Blaszkowsky, L. S., Brock, P. L., Chan, J., Das, S., Dickson, P. V., Fanta, P. T., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0032 · Cited by 632 · see citing works

Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors

Kulke, M. H., Lenz, H., Meropol, N. J., Posey, J. A., Ryan, D. P., Picus, J., Bergsland, E. K., Stuart, K. E., Tye, L., Huang, X., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9020 · Cited by 623 · see citing works

Stopping Randomized Trials Early for Benefit and Estimation of Treatment Effects Systematic Review and Meta-regression Analysis

Bassler, D. (2010) · JAMA · doi:10.1001/jama.2010.310 · Cited by 613 · see citing works

177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial

Strosberg, J. R., Caplin, M. E., Kunz, P. L., Ruszniewski, P. B., Bodei, L., Hendifar, A., Mittra, E., Wolin, E. M., Yao, J. C., Pavel, M. E., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00572-6 · Cited by 605 · see citing works

The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance

Hofland, L. J., & Lamberts, S. W. J. (2003) · Endocrine Reviews · doi:10.1210/er.2000-0001 · Cited by 476 · see citing works

Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine Tumors

Ekeblad, S., Sundin, A., Janson, E. T., Welin, S., Granberg, D. O., Kindmark, H., Dunder, K., Kozlovacki, G., Örlefors, H., Sigurd, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2053 · Cited by 470 · see citing works

Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours

Modlin, I., Pavel, M., Kidd, M., & Gustafsson, B. (2009) · Alimentary Pharmacology and Therapeutics · doi:10.1111/j.1365-2036.2009.04174.x · Cited by 392 · see citing works

Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177 Lu-Dotatate in the Phase III NETTER-1 Trial

Strosberg, J., Wolin, E. M., Chasen, B., Kulke, M. H., Bushnell, D. L., Caplin, M. E., Baum, R. P., Kunz, P. L., Hobday, T. J., Hendifar, A. E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.5865 · Cited by 391 · see citing works

Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?

Das, S., & Dasari, A. N. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01029-7 · Cited by 391 · see citing works

O 6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors

Kulke, M. H., Hornick, J. L., Frauenhoffer, C., Hooshmand, S. M., Ryan, D. P., Enzinger, P. C., Meyerhardt, J. A., Clark, J. W., Stuart, K. E., Fuchs, C. S., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1476 · Cited by 380 · see citing works

The epidemiology of metastases in neuroendocrine tumors

Riihimäki, M., Hemminki, A., Sundquist, K., Sundquist, J., & Hemminki, K. (2016) · International Journal of Cancer · doi:10.1002/ijc.30400 · Cited by 379 · see citing works

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival

Rinke, A., Wittenberg, M., Schade‐Brittinger, C., Aminossadati, B., Ronicke, E., Gress, T. M., Müller, H., Arnold, R., & for the PROMID Study Group (2016) · Neuroendocrinology · doi:10.1159/000443612 · Cited by 377 · see citing works

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

Hicks, R. J., Kwekkeboom, D. J., Krenning, E. P., Bodei, L., Grozinsky‐Glasberg, S., Arnold, R., Borbath, I., Ćwikła, J. B., Toumpanakis, C., Kaltsas, G., et al. (2017) · Neuroendocrinology · doi:10.1159/000475526 · Cited by 335 · see citing works

Rationale for the use of somatostatin analogs as antitumor agents

Susini, C., & Buscail, L. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl105 · Cited by 304 · see citing works

Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

Baudin, É., Caplin, M. E., García‐Carbonero, R., Fazio, N., Ferollà, P., Filosso, P. L., Frilling, A., de Herder, W. W., Hörsch, D., Knigge, U., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.01.003 · Cited by 292 · see citing works

Glycemic Control in Patients with Insulinoma Treated with Everolimus

Kulke, M. H., Bergsland, E. K., & Yao, J. C. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0806740 · Cited by 236 · see citing works

PIK3CA/PTEN Mutations and Akt Activation as Markers of Sensitivity to Allosteric mTOR inhibitors

Meric-Bernstam, F., Akcakanat, A., Chen, H.-Q., Do, K., Sangai, T., Adkins, F. C., González-Angulo, A., Rashid, A., Crosby, K., Dong, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2123 · Cited by 228 · see citing works

Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study

Caplin, M. E., Pavel, M. E., Ćwikła, J. B., Phan, A. T., Raderer, M., Sedláčková, E., Cadiot, G., Wolin, E. M., Capdevila, J., Wall, L. R., et al. (2016) · Endocrine Related Cancer · doi:10.1530/erc-15-0490 · Cited by 226 · see citing works

Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study

Faivre, S. J., Niccoli, P., Castellano, D., Valle, J. W., Hammel, P. R., Raoul, J., Vinik, A. I., Cutsem, E. V., Bang, Y.-J., Lee, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw561 · Cited by 194 · see citing works

Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177 Lu-Octreotate

Ezziddin, S., Attassi, M., Yong-Hing, C. J., Ahmadzadehfar, H., Willinek, W. A., Grünwald, F., Guhlke, S., Biersack, H., & Sabet, A. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.125336 · Cited by 191 · see citing works

Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms

Grozinsky‐Glasberg, S., Shimon, I., Korbonits, M., & Grossman, A. B. (2008) · Endocrine Related Cancer · doi:10.1677/erc-07-0288 · Cited by 184 · see citing works

Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors

Cives, M., Ghayouri, M., Morse, B. G., Brelsford, M., Black, M., Rizzo, A. J., Meeker, A. K., & Strosberg, J. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0147 · Cited by 167 · see citing works

Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study

Carlsen, E. A., Fazio, N., Granberg, D. O., Grozinsky‐Glasberg, S., Ahmadzadehfar, H., Grana, C. M., Zandee, W. T., Ćwikła, J. B., Walter, M. A., Oturai, P., et al. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0424 · Cited by 159 · see citing works

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents

Pavel, M. E., Valle, J. W., Eriksson, B. K., Rinke, A., Caplin, M. E., Chen, J., Costa, F. P., Falkerby, J., Fazio, N., Gorbounova, V. A., et al. (2017) · Neuroendocrinology · doi:10.1159/000471880 · Cited by 156 · see citing works

Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors

Bodei, L., Kidd, M. S., Modlin, I. M., Severi, S., Drozdov, I. A., Nicolini, S., Kwekkeboom, D. J., Krenning, E. P., Baum, R. P., & Paganelli, G. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3250-z · Cited by 145 · see citing works

Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial

Ferollà, P., Brizzi, M. P., Meyer, T., Mansoor, W., Mazières, J., Cao, C. D., Léna, H., Berruti, A., Damiano, V., Buikhuisen, W. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30681-2 · Cited by 138 · see citing works

Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor–Expressing Neuroendocrine Tumors

Delpassand, E. S., Samarghandi, A., Zamanian, S., Wolin, E. M., Hamiditabar, M., Espenan, G. D., Erion, J. L., O’Dorisio, T. M., Kvols, L. K., Simón, J., et al. (2014) · Pancreas · doi:10.1097/mpa.0000000000000113 · Cited by 136 · see citing works

Octreotide and the mTOR Inhibitor RAD001 (Everolimus) Block Proliferation and Interact with the Akt-mTOR-p70S6K Pathway in a Neuro-Endocrine Tumour Cell Line

Grozinsky‐Glasberg, S., Franchi, G. M., Teng, M. J., Leontiou, C. A., de Oliveira, A. R., Ciaramella, P. D., Salahuddin, N., Korbonits, M., & Grossman, A. B. (2007) · Neuroendocrinology · doi:10.1159/000111501 · Cited by 130 · see citing works

Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors

Florio, T. (2007) · Frontiers in bioscience · doi:10.2741/2722 · Cited by 128 · see citing works

Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study

Pavel, M. E., Baudin, É., Öberg, K. E., Hainsworth, J. D., Voi, M., Rouyrre, N., Peeters, M., Gross, D. J., & Yao, J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx193 · Cited by 128 · see citing works

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy

García‐Carbonero, R., Rinke, A., Valle, J. W., Fazio, N., Caplin, M. E., Gorbounova, V. A., O’Connor, J. M., Eriksson, B. K., Sørbye, H., Kulke, M. H., et al. (2017) · Neuroendocrinology · doi:10.1159/000473892 · Cited by 123 · see citing works

Long-term results of PRRT in advanced bronchopulmonary carcinoid

Mariniello, A., Bodei, L., Tinelli, C., Baio, S. M., Gilardi, L., Colandrea, M., Papi, S., Valmadre, G., Fazio, N., Galetta, D., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3190-7 · Cited by 118 · see citing works

Treatment with the Radiolabelled Somatostatin Analog 177Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

Sansovini, M., Severi, S., Ambrosetti, A., Monti, M., Nanni, O., Sarnelli, A., Bodei, L., Garaboldi, L., Bartolomei, M., & Paganelli, G. (2013) · Neuroendocrinology · doi:10.1159/000348394 · Cited by 114 · see citing works

Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy

Claringbold, P. G., & Turner, J. H. (2015) · Neuroendocrinology · doi:10.1159/000434723 · Cited by 111 · see citing works

Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors

Panzuto, F., Rinzivillo, M., Fazio, N., de Braud, F., Luppi, G., Zatelli, M. C., Lugli, F., Tomassetti, P., Riccardi, F., Nuzzo, C. M. A., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0037 · Cited by 101 · see citing works

Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence

Lee, L., Ito, T., & Jensen, R. T. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1476492 · Cited by 101 · see citing works

Specific efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumours of the small intestine

Sabet, A., Dautzenberg, K., Haslerud, T. M., Aouf, A., Sabet, A., Simon, B., Mayer, K. T., Biersack, H., & Ezziddin, S. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3041-6 · Cited by 100 · see citing works

Evaluation of Lanreotide Depot/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment (Elect): A Randomized, Double-Blind, Placebo-Controlled Trial

Vinik, A. I., Wolin, E. M., Liyanage, N., Gomez-Panzani, E. L., & Fisher, G. A. (2016) · Endocrine Practice · doi:10.4158/ep151172.or · Cited by 100 · see citing works

Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies

Ito, T., Lee, L., & Jensen, R. T. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1236916 · Cited by 99 · see citing works

Angiogenesis in Neuroendocrine Tumors: Therapeutic Applications

Scoazec, J. (2012) · Neuroendocrinology · doi:10.1159/000338371 · Cited by 95 · see citing works

The origin of neuroendocrine tumors and the neural crest saga

Rosaí, J. (2011) · Modern Pathology · doi:10.1038/modpathol.2010.166 · Cited by 95 · see citing works

Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors

Spada, F., Antonuzzo, L., Marconcini, R., Radice, D., Antonuzzo, A., Ricci, S., Costanzo, F. D., Fontana, A., Gelsomino, F., Luppi, G., et al. (2016) · Neuroendocrinology · doi:10.1159/000444087 · Cited by 95 · see citing works

The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors

Ramirez, R. A., Beyer, D. T., Chauhan, A., Boudreaux, J. P., Wang, Y., & Woltering, E. A. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0470 · Cited by 95 · see citing works

Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results

Pavel, M., Ćwikła, J. B., Lombard‐Bohas, C., Borbath, I., Shah, T., Pape, U. F., Capdevila, J., Panzuto, F., Thanh, X.-M. T., Houchard, A., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.06.056 · Cited by 92 · see citing works

Effect of Temozolomide in Patients with Metastatic Bronchial Carcinoids

Crona, J., Fanola, I., Lindholm, D. P., Antonodimitrakis, P. C., Öberg, K., Eriksson, B., & Granberg, D. O. (2013) · Neuroendocrinology · doi:10.1159/000354760 · Cited by 90 · see citing works

Digestive System Tumours

Sobin, L. H., Gospodarowicz, M. K., & Wittekind, C. (2010) · TNM Online · doi:10.1002/9780471420194.tnmc09.pub2 · Cited by 85 · see citing works

Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study

Caplin, M. E., Pavel, M., Phan, A. T., Ćwikła, J. B., Sedláčková, E., Thanh, X.-M. T., Wolin, E. M., Ruszniewski, P. B., & on behalf of the CLARINET Investigators (2020) · Endocrine · doi:10.1007/s12020-020-02475-2 · Cited by 85 · see citing works

PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors

Wolin, E. M. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.02.016 · Cited by 80 · see citing works

Treatment with Octreotide Does Not Reduce Tumor Uptake of 68Ga-DOTATATE as Measured by PET/CT in Patients with Neuroendocrine Tumors

Haug, A. R., Rominger, A., Mustafa, M., Auernhammer, C. J., Göke, B., Schmidt, G. P., Wängler, B., Cumming, P. D., Bartenstein, P., & Hacker, M. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.089276 · Cited by 78 · see citing works

Everolimus in combination with octreotide long‐acting repeatable in a first‐line setting for patients with neuroendocrine tumors: An ITMO group study

Bajetta, E., Catena, L., Fazio, N., Pusceddu, S., Biondani, P., Blanco, G., Ricci, S., Aieta, M., Pucci, F., Valente, M., et al. (2014) · Cancer · doi:10.1002/cncr.28726 · Cited by 74 · see citing works

The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy

Yordanova, A., Wicharz, M. M., Mayer, K. T., Brossart, P., Gonzalez-Carmona, M. A., Strassburg, C. P., Fimmers, R., Essler, M., & Ahmadzadehfar, H. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0947 · Cited by 73 · see citing works

Capecitabine and streptozocin±cisplatin in advanced gastroenteropancreatic neuroendocrine tumours

Meyer, T., Qian, W., Caplin, M. E., Armstrong, G., Lao-Sirieix, S.-H., Hardy, R., Valle, J. W., Talbot, D. C., Cunningham, D., Reed, N., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.12.011 · Cited by 71 · see citing works

Long‐term results of patients with malignant carcinoid syndrome receiving octreotide LAR

Toumpanakis, C., Garland, J., Marelli, L., Srirajaskanthan, R., SOH, J., Davies, P., Buscombe, J. R., & Caplin, M. E. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04083.x · Cited by 64 · see citing works

Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters

Faggiano, A., Modica, R., Calzo, F. L., Camera, L., Napolitano, V., Altieri, B., de Cicco, F., Bottiglieri, F., Sesti, F. F., Badalamenti, G., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz007 · Cited by 64 · see citing works

Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms

Pellat, A., Dreyer, C., Couffignal, C., Walter, T., Lombard‐Bohas, C., Niccoli, P., Seitz, J. F., Hentic, O., André, T., Coriat, R., et al. (2018) · Neuroendocrinology · doi:10.1159/000487237 · Cited by 60 · see citing works

Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case–control study

Feola, T., Puliani, G., Sesti, F. F., Modica, R., Centello, R., Minotta, R., Cannavale, G., Meglio, S. D., Vito, V. D., Lauretta, R., et al. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01715-0 · Cited by 60 · see citing works

Hepatic arterial embolization in patients with neuroendocrine tumors

Prete, M. D., Fiore, F., Modica, R., Marotta, V., Marciello, F., Ramundo, V., Sarno, A. D., Carratù, A., di Roseto, C. D. L., Tafuto, S., et al. (2014) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-33-43 · Cited by 59 · see citing works

Diffuse Endocrine System, Neuroendocrine Tumors and Immunity: What’s New?

Ameri, P., & Ferone, D. (2012) · Neuroendocrinology · doi:10.1159/000334612 · Cited by 57 · see citing works

Future Aspects of Somatostatin- Receptor-Mediated Therapy

Öberg, K. (2004) · Neuroendocrinology · doi:10.1159/000080743 · Cited by 55 · see citing works

Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas

Frizziero, M., Spada, F., Lamarca, Á., Kordatou, Z., Barriuso, J., Nuttall, C., McNamara, M. G., Hubner, R. A., Mansoor, W., Manoharan, P., et al. (2019) · Neuroendocrinology · doi:10.1159/000497336 · Cited by 50 · see citing works

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours

Zurita, A. J., Khajavi, M., Wu, H.-K., Tye, L., Huang, X., Kulke, M. H., Lenz, H. J., Meropol, N. J., Carley, W. W., DePrimo, S. E., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.73 · Cited by 49 · see citing works

90Y/177Lu-DOTATOC: From Preclinical Studies to Application in Humans

Uccelli, L., Boschi, A., Cittanti, C., Martini, P., Panareo, S., Tonini, E., Nieri, A., Urso, L., Caracciolo, M., Lodi, L., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091463 · Cited by 46 · see citing works

Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors

Barrea, L., Muscogiuri, G., Modica, R., Altieri, B., Pugliese, G., Minotta, R., Faggiano, A., Colao, A., & Savastano, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.649496 · Cited by 45 · see citing works

Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead

Colao, A., de Nigris, F., Modica, R., & Claudio Napoli, A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.604341 · Cited by 44 · see citing works

The safety of available treatments options for neuroendocrine tumors

Faggiano, A., Calzo, F. L., Pizza, G., Modica, R., & Colao, A. A. L. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1354984 · Cited by 42 · see citing works

Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review

Chan, D. L. H., Ferone, D., Albertelli, M., Pavlakis, N., Segelov, E., & Singh, S. (2017) · Endocrine · doi:10.1007/s12020-017-1360-z · Cited by 42 · see citing works

Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor

Lamberti, G., Faggiano, A., Brighi, N., Tafuto, S., Ibrahim, T., Brizzi, M. P., Pusceddu, S., Albertelli, M., Massironi, S., Panzuto, F., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz035 · Cited by 42 · see citing works

Inflammation-Based Index and 68Ga-DOTATOC PET–Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with 90Y-DOTATOC

Pauwels, E., Binnebeek, S. V., Vandecaveye, V., Baete, K., Vanbilloen, H. P., Koole, M. J. B., Mottaghy, F. M., Haustermans, K. M., Clément, P. M., Nackaerts, K., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.236935 · Cited by 42 · see citing works

Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study

Brighi, N., Panzuto, F., Modica, R., Gelsomino, F., Albertelli, M., Pusceddu, S., Massironi, S., Lamberti, G., Rinzivillo, M., Faggiano, A., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0403 · Cited by 36 · see citing works

Somatostatin Analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life

Faggiano, A., Carratù, A. C., Guadagno, E., Tafuto, S., Tatangelo, F., Riccardi, F., Mocerino, C., Palmieri, G., Damiano, V., Siciliano, R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6686 · Cited by 35 · see citing works

Quality of Life in Patients with Neuroendocrine Neoplasms: The Role of Severity, Clinical Heterogeneity, and Resilience

Scandurra, C., Modica, R., Maldonato, N. M., Dolce, P., Dipietrangelo, G. G., Centello, R., Vito, V. D., Bottiglieri, F., de Cicco, F., Giannetta, E., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa760 · Cited by 35 · see citing works

Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group

ELIOS, O. B. O., Faggiano, A., Maio, S. D., Mocerino, C., Ottaviano, M., Divitiis, C. D., Guarnotta, V., Dolce, P., Modica, R., Puliafito, I., et al. (2019) · Endocrine · doi:10.1007/s12020-019-01894-0 · Cited by 34 · see citing works

PRRT: identikit of the perfect patient

Albertelli, M., Dotto, A., Dato, C. D., Malandrino, P., Modica, R., Versari, A., Colao, A. A. L., Ferone, D., Faggiano, A., & on behalf of, N. I. K. E. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09581-6 · Cited by 34 · see citing works

Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors

Narayanan, S., & Kunz, P. L. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0012 · Cited by 32 · see citing works

When should genetic testing be performed in patients with neuroendocrine tumours?

O’Shea, T., & Druce, M. R. (2017) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-017-9430-3 · Cited by 31 · see citing works

PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme?

Haug, A. R. (2020) · EJNMMI Research · doi:10.1186/s13550-020-00623-3 · Cited by 31 · see citing works

Phase I Study of Pasireotide (SOM 230) and Everolimus (RAD001) in Advanced Neuroendocrine Tumors

Chan, J., Ryan, D., Zhu, A., Abrams, T., Wolpin, B., Malinowski, P., Regan, E., Fuchs, C., & Kulke, M. (2012) · Endocrine-Related Cancer · doi:10.1530/erc-11-0382 · Cited by 30 · see citing works

Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks

Fanciulli, G., Molfetta, S. D., Dotto, A., Florio, T., Feola, T., Rubino, M., de Cicco, F., Colao, A., Faggiano, A., & NIKE Group (2020) · Journal of Clinical Medicine · doi:10.3390/jcm10010088 · Cited by 29 · see citing works

Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study

Fisher, G. A., Wolin, E. M., Liyanage, N., Lowenthal, S. P., Mirakhur, B., Pommier, R. F., Shaheen, M. F., Vinik, A. I., & on behalf of the ELECT Study Group (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0284 · Cited by 27 · see citing works

Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches

Lania, A. G., Ferraù, F., Rubino, M., Modica, R., Colao, A. A. L., & Faggiano, A. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.651438 · Cited by 27 · see citing works

Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours

Laskaratos, F., Walker, M., Naik, K., Maragkoudakis, E., Oikonomopoulos, N., Grant, L. A., Meyer, T., Caplin, M. E., & Toumpanakis, C. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.349 · Cited by 26 · see citing works

Capecitabine-Temozolomide in Advanced Grade 2 and Grade 3 Neuroendocrine Neoplasms: Benefits of Chemotherapy in Neuroendocrine Neoplasms with Significant 18FDG Uptake

Ostwal, V. S., Basu, S. K., BHARGAVA, P. G., Shah, M. J., Parghane, R. V., Srinivas, S., Chaudhari, V. A., BHANDARE, M. S., Shrikhande, S. V., & Ramaswamy, A. (2020) · Neuroendocrinology · doi:10.1159/000511987 · Cited by 24 · see citing works

Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature

Faggiano, A., Malandrino, P., Modica, R., Agrimi, D., Aversano, M., Bassi, V., Giordano, E., Guarnotta, V., Logoluso, F. A., Messina, E., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0420 · Cited by 22 · see citing works

Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors

Martins, D., Spada, F., Lambrescu, I. M., Rubino, M., Cella, C. A., Gibelli, B., Grana, C. M., Ribero, D., Bertani, E., Ravizza, D., et al. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0506-5 · Cited by 21 · see citing works

Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study

Rinzivillo, M., Fazio, N., Pusceddu, S., Spallanzani, A., Ibrahim, T., Campana, D., Marconcini, R., Partelli, S., Badalamenti, G., Brizzi, M. P., et al. (2018) · Pancreatology · doi:10.1016/j.pan.2018.01.005 · Cited by 20 · see citing works

Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms

Tafuto, S., von Arx, C., Capozzi, M., Tatangelo, F., Mura, M., Modica, R., Barretta, M. L., Sarno, A. D., Tornesello, M. L., Colao, A., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081224 · Cited by 18 · see citing works

Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study

Massironi, S., Campana, D., Pusceddu, S., Albertelli, M., Faggiano, A., Panzuto, F., Smiroldo, V., Andreasi, V., Rossi, R. E., Maggio, I., et al. (2020) · Digestive and Liver Disease · doi:10.1016/j.dld.2020.09.031 · Cited by 18 · see citing works

Open issues on G3 neuroendocrine neoplasms: back to the future

Zatelli, M. C., Guadagno, E., Messina, E., Calzo, F. L., Faggiano, A., Colao, A., & _, _. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0507 · Cited by 17 · see citing works

Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives

On behalf of NIKE Group, Gallo, M., Malandrino, P., Fanciulli, G., Rota, F., Faggiano, A., & Colao, A. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2407-5 · Cited by 15 · see citing works

In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy

Syguła, A., Ledwoń, A., Hasse-Lazar, K., Jurecka‐Lubieniecka, B., Michalik, B., Paliczka-Cieślik, E., Zeman, M., Chmielik, E., Sczasny, J., Jarząb, B., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05792-y · Cited by 15 · see citing works

1161MO Lanreotide autogel (LAN) and temozolomide (TMZ) combination therapy in progressive thoracic neuroendocrine tumours (TNETs): ATLANT study results

Ferollà, P., Berruti, A., Spada, F., Brizzi, M. P., Ibrahim, T., Colao, A. A. L., Faggiano, A., Marconcini, R., Vaccaro, V., Giuffrida, D., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.1374 · Cited by 11 · see citing works

Sunitinib-Induced Hypothyroidism and Survival in Pancreatic Neuroendocrine Tumors

Mathew, A., Führer, D., & Lahner, H. (2021) · Hormone and Metabolic Research · doi:10.1055/a-1658-3077 · Cited by 11 · see citing works

Clinicopathological and genetic analyses of small cell neuroendocrine carcinoma of the prostate: Histological features for accurate diagnosis and toward future novel therapies

Ida, A., Okubo, Y., Kasajima, R., Washimi, K., Sato, S., Yoshioka, E., Osaka, K., Suzuki, T., Yamamoto, Y., Yokose, T., et al. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153731 · Cited by 10 · see citing works

First long-term results on efficacy and safety of long-acting pasireotide in combination with everolimus in patients with advanced carcinoids (NET) of the lung/thymus: Phase II LUNA trial.

Baudin, É., Berruti, A., Giuliano, M., Mansoor, W., Bobirca, C., Houtsma, E., Fagan, N., Öberg, K. E., & Ferollà, P. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.8574 · Cited by 8 · see citing works

High-Dose Lanreotide in the Treatment of Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: A Case Report

Fraeyenhove, F. V., Meireson, N., Terriere, L., Willemsen, P. J., Kunnen, J., Mattelaer, C., Acker, F. V., & Schrijvers, D. L. A. L. (2014) · Case Reports in Oncology · doi:10.1159/000360732 · Cited by 7 · see citing works

Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors

Gao, H., Dong, J., Zhang, W., Xu, H., Ye, L., Li, H., Ni, Q., Wang, W., & Liu, L. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.08.008 · Cited by 4 · see citing works

Second-line therapy for patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma

Swain, J. (2018) · http://isrctn.com/ · doi:10.1186/isrctn10996604 · Cited by 1 · see citing works

Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation

Dhoundiyal, S., Srivastava, S., Kumar, S., Singh, G., Ashique, S., Pal, R., Mishra, N., & Taghizadeh-Hesary, F. (2024) · European Journal of Medical Research · doi:10.1186/s40001-023-01627-0 · Cited by 144 · see citing works

Molecular Classification of Gastrointestinal and Pancreatic Neuroendocrine Neoplasms: Are We Ready for That?

Uccella, S. (2024) · Endocrine Pathology · doi:10.1007/s12022-024-09807-2 · Cited by 32 · see citing works

Lipid Metabolism and Homeostasis in Patients with Neuroendocrine Neoplasms: From Risk Factor to Potential Therapeutic Target

Modica, R., Salvia, A. L., Liccardi, A., Cannavale, G., Minotta, R., Benevento, E., Faggiano, A., & Colao, A. A. L. (2022) · Metabolites · doi:10.3390/metabo12111057 · Cited by 29 · see citing works

Recent advances and future challenges in the diagnosis of neuroendocrine neoplasms

Modica, R., Benevento, E., Liccardi, A., Cannavale, G., Minotta, R., Iasi, G. D., & Colao, A. A. L. (2024) · Minerva Endocrinology · doi:10.23736/s2724-6507.23.04140-4 · Cited by 22 · see citing works

Psychological distress and resilience in patients with gastroenteropancreatic neuroendocrine tumor

Lili, S., Cao, Y., Li, J., Lu, M., & Tang, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.947998 · Cited by 20 · see citing works

Current understanding of pathogenetic mechanisms in neuroendocrine neoplasms

Modica, R., Liccardi, A., Minotta, R., Cannavale, G., Benevento, E., & Colao, A. A. L. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2279540 · Cited by 20 · see citing works

Comparison between Endoscopic Submucosal Dissection and Transanal Endoscopic Microsurgery in Early Rectal Neuroendocrine Tumor Patients: A Meta-Analysis

Wang, F.-G., Jiang, Y., Liu, C., & Qi, H. (2023) · Journal of Investigative Surgery · doi:10.1080/08941939.2023.2278191 · Cited by 16 · see citing works

Somatostatin Receptor Expression of Gastroenteropancreatic Neuroendocrine Tumors: A Comprehensive Analysis in the Era of Somatostatin Receptor PET Imaging

Maratta, M. G., Al‐Toubah, T., Montilla-Soler, J., Pellè, E., Haider, M., El-Haddad, G. E., & Strosberg, J. (2025) · Cancers · doi:10.3390/cancers17121937 · Cited by 15 · see citing works

Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons

Modica, R., Salvia, A. L., Liccardi, A., Cozzolino, A., Sarno, A. D., Russo, F., Colao, A., Faggiano, A., & on behalf of NIKE group (2024) · Endocrine · doi:10.1007/s12020-024-03767-7 · Cited by 14 · see citing works

Consideration of quality of life in the treatment decision-making for patients with advanced gastroenteropancreatic neuroendocrine tumors

Naraev, B. G., Mailman, J. A., Halfdanarson, T. R., Soares, H. P., Mittra, E., & Hallet, J. I. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2207829 · Cited by 12 · see citing works

Investigating the causal relationship between gut microbiota and gastroenteropancreatic neuroendocrine neoplasms: a bidirectional Mendelian randomization study

Zhang, C., Jiang, S.-J., Cao, J., Xu, Y. J., Wang, X., Li, R., & Miao, Z. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1420167 · Cited by 11 · see citing works

Functioning neuroendocrine tumors (NET): Minimum requirements for a NET specialist

Spada, F., Rossi, R. E., Modica, R., Gelsomino, F., Rinzivillo, M., Rubino, M., Pisa, E., Salvia, A. L., & Fazio, N. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102907 · Cited by 11 · see citing works

Gender Differences in Lung Neuroendocrine Tumors: A Single-Center Experience

Liccardi, A., Colao, A., & Modica, R. (2024) · Neuroendocrinology · doi:10.1159/000539412 · Cited by 11 · see citing works

Role of Bone Metastases in Lung Neuroendocrine Neoplasms: Clinical Presentation, Treatment and Impact on Prognosis

Modica, R., Benevento, E., Altieri, B., Minotta, R., Liccardi, A., Cannavale, G., Iasi, G. D., & Colao, A. A. L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168957 · Cited by 9 · see citing works

Resistance of neuroendocrine tumours to somatostatin analogs

Angelousi, A., Koumarianou, A., Chatzellis, E., & Kaltsas, G. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2166488 · Cited by 6 · see citing works

Impact of treatment on quality of life in neuroendocrine neoplasm survivors

Modica, R., Benevento, E., Salvia, A. L., Mazzilli, R., Pandozzi, C., Pecora, G., Barrea, L., Colao, A. A. L., Faggiano, A., & on behalf of NIKE Group (2025) · Endocrine Related Cancer · doi:10.1530/erc-24-0303 · Cited by 7 · see citing works

Gender impact on pancreatic neuroendocrine neoplasm (PanNEN) prognosis according to survival nomograms

Salvia, A. L., Modica, R., Spada, F., & Rossi, R. E. (2024) · Endocrine · doi:10.1007/s12020-024-04129-z · Cited by 6 · see citing works

Editorial: Neuroendocrine tumors: the road to precision medicine

Salvia, A. L., Giuffrida, D., & Modica, R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1253319 · Cited by 6 · see citing works

Alpha therapies: where and when is the future in neuroendocrine tumours?

Vorster, M., Grana, C. M., Travascio, L., & Sathekge, M. M. (2025) · Clinical and Translational Imaging · doi:10.1007/s40336-025-00692-1 · Cited by 5 · see citing works

How the diffuse neuroendocrine system shapes health, homeostasis, and cancer

Salzet, M. (2025) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2025.101216 · Cited by 4 · see citing works

Efficiency and Safety of Targeted Alpha Therapy in Metastatic Neuroendocrine Tumors

Lee, D. Y., & Kim, Y.-I. (2024) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005404 · Cited by 4 · see citing works

Current Clinical Trial Landscape of Gastroenteropancreatic Neuroendocrine Tumors: A New Era of Landmark Trials

Peshin, S., Modi, S., Babakhanlou, R., & Arshad, J. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186522 · Cited by 3 · see citing works

The unmet information needs, quality of life, and care experiences of patients with neuroendocrine tumours (NETs) at follow-up: 6 months from diagnosis

Guccione, L., Gough, K., Drosdowsky, A., Price, T. J., Pavlakis, N., Wyld, D., Ransom, D. T., Michael, M., & Schofield, P. E. (2023) · Supportive Care in Cancer · doi:10.1007/s00520-023-08034-5 · Cited by 3 · see citing works

The association between non-HDL cholesterol and high-grade pancreatic neuroendocrine neoplasms

Zhou, H., Zhu, Y., Qin, B., Liu, Y., Wang, Z., Guo, C., Wang, J., & Chen, X. (2024) · Endocrine · doi:10.1007/s12020-024-03910-4 · Cited by 3 · see citing works

Tumor Growth Rate in Neuroendocrine Neoplasms: An Additional Tool for Treatment Strategies?

Modica, R., Liccardi, A., Benevento, E., Minotta, R., Iasi, G. D., Nola, M. D., Coletta, M., & Colao, A. (2025) · Medicina · doi:10.3390/medicina61101852 · Cited by 2 · see citing works

An update on the safety of lanreotide autogel for the treatment of patients with neuroendocrine tumors

Sood, A., Munir, M., Syed, O., Mehta, V., Kaur, R., Kumar, A. P., Sridhar, A., Sood, A., & Gupta, R. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2365823 · Cited by 2 · see citing works

Innovative approaches in predicting outcomes for rectal neuroendocrine tumors

Nassar, M., Baraka, B., & Talal, A. H. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i6.100517 · Cited by 2 · see citing works

Authorship of Italian medical literature on neuroendocrine neoplasms: any gender gap?

Rossi, R. E., Salvia, A. L., Modica, R., & Spada, F. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02347-w · Cited by 1 · see citing works

Appendicular Neuroendocrine Tumours: An Unusual Cause of Hydronephrosis

Puia, D., Ivănuță, M., & Pricop, C. (2024) · Cureus · doi:10.7759/cureus.62774

A prognostic nomogram of stage IV gastroenteropancreatic neuroendocrine neoplasms establishment based on the SEER database

Chen, S., Feng, Y., Zhang, W., Cheng, L., Xu, J., Huang, Y., Hong, C., Gu, L., He, Y., Zhang, C., et al. (2025) · Gastrointestinal Tumors · doi:10.48130/git-0025-0010

Clinical characteristics and survival of patients with calcitonin-secreting neuroendocrine neoplasms: experience from a series of 71 patients

Popovic, B. M., Kovačević, V. E., Ilic, D. S., Palibrk, M. O., Radić, L., Krstić, K., Micev, M. T., Menković, N., Petković, A., Artiko, V. M., et al. (2025) · Endocrine · doi:10.1007/s12020-025-04439-w

Future Trends in NEN Care: QoL and Multidisciplinary Care

Modica, R., Liccardi, A., Benevento, E., & Colao, A. A. L. (2025) · Endocrinology · doi:10.1007/978-3-030-67823-4_18-1

Bone metastases in pheochromocytomas and paragangliomas: a narrative review of presentation, diagnosis and management

Contreras-Saldarriaga, J. E., & Loaiza-Alzate, M. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1671486

Future Trends in NEN Care: QoL and Multidisciplinary Care

Modica, R., Liccardi, A., Benevento, E., & Colao, A. A. L. (2025) · Endocrinology · doi:10.1007/978-3-031-83281-9_18

Comparison of somatostatin analogues on glucose metabolism: A systematic review and network Meta-Analysis of randomized controlled trials

Zhao, Y., Tao, Y., Zhu, Y., Li, S., Guo, H., Huang, Y., Huang, Y., & Fang, C. (2026) · Endocrine · doi:10.1007/s12020-026-04560-4

Flushing: Neuroendocrine Mechanisms and a Structured Diagnostic Approach

García-Sáenz, M. R., Sosa, E., Ferreira‐Hermosillo, A., Ramírez-Renteria, C., López-Juárez, N., & Espinosa-Cárdenas, E. (2026) · Clinical Endocrinology · doi:10.1111/cen.70157

Beyond Tumor Control in Sporadic Neuroendocrine Tumor: Metabolic and Bone Health During Treatment with Somatostatin Analogs

Modica, R., Liccardi, A., Minotta, R., Benevento, E., Iasi, G. D., Nola, M. D., Coletta, M., & Colao, A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15176927

Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives

Hijioka, S., Morizane, C., Ikeda, M., Ishii, H., Okusaka, T., & Furuse, J. (2021) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyab076 · Cited by 18 · see citing works

Neuroendocrine neoplasms: Evolving and future treatments

Spyroglou, A., Bramis, K., & Alexandraki, K. (2021) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2021.05.002 · Cited by 10 · see citing works

Medikamentöse Therapie neuroendokriner Neoplasien des Gastrointestinaltrakts

Fottner, C., & Weber, M. M. (2018) · Wiener klinisches Magazin · doi:10.1007/s00740-018-0238-x

Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review.

Pusceddu, S., Braud, F. D., Festinese, F., Bregant, C., Lorenzoni, A., Maccauro, M., Milione, M., Concas, L., Formisano, B., Leuzzi, L., et al. (2015) · Future Oncology · doi:10.2217/fon.15.86 · Cited by 10 · see citing works

Genomic Profiles and Current Therapeutic Agents in Neuroendocrine Neoplasms

Ohmoto, A., & Morizane, C. (2019) · Current Drug Targets · doi:10.2174/1389450119666191014105211 · Cited by 3 · see citing works